Exogenous glucagon-like peptide-1 (GLP-1) attenuates the glycaemic response to small intestinal nutrient in the critically ill.

The effect of exogenous glucagon-like peptide-1 (GLP-1) compared to placebo on glycaemia in critically ill patients during small intestinal feeding

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000093280

Enrollment

Registered

2009-02-10

Start date

2008-07-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The primary objective of this study is to establish if glucagon-like peptide-1 (a hormone released from the gastrointestinal) has an effect on blood sugar levels in patients who are critically ill

Interventions

Glucagon-like peptide-1 at 1.2pmol.kg.min infused at 1ml/min between t=0-270min. Participants will cross-over to the other arm (i.e. GLP-1 to control and vice-versa) on the next consecutive day (as GLP-1 is rapidly metabolised with a t1/2 < 5mins)

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

Inclusion criteria Critically ill patients who require artificial ventilation Likely to be ventilated for >48hrs Suitable to receive enteral nutrition via naso-jejunal feeding tube

Exclusion criteria

Age <18 Age>85 Pregnancy Small bowel obstruction History of diabetes Previous surgery on the oesophagus, stomoach or duodenum Any gastrointestinal surgery on this admission

Outcome results